Poseida Therapeutics, Inc. (NASDAQ:PSTX - Get Free Report) Chairman Mark J. Gergen sold 30,000 shares of the company's stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $9.46, for a total transaction of $283,800.00. Following the completion of the transaction, the chairman now owns 651,291 shares of the company's stock, valued at $6,161,212.86. This trade represents a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Poseida Therapeutics Stock Performance
NASDAQ:PSTX opened at $9.51 on Thursday. Poseida Therapeutics, Inc. has a 12-month low of $1.87 and a 12-month high of $9.52. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $926.89 million, a P/E ratio of -15.10 and a beta of 1.64. The stock has a 50-day moving average price of $4.29 and a 200 day moving average price of $3.45.
Wall Street Analyst Weigh In
A number of research firms have issued reports on PSTX. William Blair reiterated a "market perform" rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. BTIG Research reissued a "neutral" rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Piper Sandler downgraded shares of Poseida Therapeutics from an "overweight" rating to a "neutral" rating and set a $10.00 price objective on the stock. in a research report on Monday, December 2nd. HC Wainwright reissued a "neutral" rating and issued a $9.00 target price (down from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. Finally, Cantor Fitzgerald lowered Poseida Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 26th. Five investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $9.50.
Missed Nvidia? Buy Elon Musk’s “Silent Partner”
From Brownstone Research | Ad
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks.
Today, it’s probably the most popular stock in the world.
I believe this Elon Musk “silent partner” could be the next big AI winner.
So please click here to see the details because a lot of people could get rich.
Read Our Latest Stock Report on PSTX
Institutional Trading of Poseida Therapeutics
Several hedge funds have recently bought and sold shares of PSTX. Marshall Wace LLP purchased a new position in shares of Poseida Therapeutics in the 2nd quarter worth $31,000. Rothschild Investment LLC bought a new position in shares of Poseida Therapeutics in the second quarter worth about $35,000. Principal Financial Group Inc. purchased a new position in shares of Poseida Therapeutics during the second quarter worth approximately $35,000. Virtu Financial LLC purchased a new position in Poseida Therapeutics during the 3rd quarter worth $37,000. Finally, Intech Investment Management LLC purchased a new stake in Poseida Therapeutics in the third quarter worth about $46,000. Hedge funds and other institutional investors own 46.87% of the company's stock.
Poseida Therapeutics Company Profile
(
Get Free Report)
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
